Research Article

Expression Analysis of Fibronectin Type III Domain-Containing (FNDC) Genes in Inflammatory Bowel Disease and Colorectal Cancer

Table 1

IBD patients’ characteristics.

IBD nonaffectedUC affectedCD affected

Number of subjects11 (4 CU, 7 CD)88
Age, median years (range)45 (27-60)39 (26-54)32 (28-60)
Age at first diagnosis ()
Sex (male/female)6/57/13/5
Localization
 Ileum504
 Ascending colon510
 Transverse colon641
 Descending colon511
 Sigmoid colon131
 Rectum411
Mayo Score
 No activity (0-1)40NA
 Mild disease (2-5)07NA
 Moderate/severe disease (≥6)01NA
Harvey-Bradshaw Index
 Remission (<5)4NA4
 Mild disease (5-7)3NA3
 Moderate disease (8-16)0NA1
 Severe disease (>16)0NA0
Montreal classification
 E1, E2, E30/1/30/3/5NA
 A1, A2, A30/6/1NA0/7/1
 L1, L2, L3, L41/3/3/0NA1/4/3/0
 B1, B2, B3, B3p1/4/1/1NA1/4/1/2
Medication
 No000
 5-ASA251
 Corticosteroids222
 Immunosuppressives220
 Biologicals936
 Small molecule drugs001
 As combination432
Laboratory findings ()
 Erythrocytes (1012/L)
 Leukocytes (109/L)
 Thrombocytes (109/L)
 Hemoglobin (g/dL)
 CRP (mg/L)
 Sodium (mmol/L)
 Potassium (mmol/L)

Each column lists characteristics for all patients contributing with samples to the corresponding sample group. Abbreviations: E1: ulcerative proctitis; E2: left-sided UC; E3: pancolitis; A1: below 16 y; A2: between 17 and 40 y; A3: above 40 y; L1: ileal; L2: colonic; L3: ileocolonic; L4: isolated upper disease; B1: nonstricturing, nonpenetrating; B2: stricturing; B3: penetrating; B3p: perianal disease; 5-ASA: 5-aminosalicylic acid; CRP: C-reactive protein.